Kyverna Therapeutics Statistics
Total Valuation
KYTX has a market cap or net worth of $603.61 million. The enterprise value is $554.58 million.
| Market Cap | 603.61M |
| Enterprise Value | 554.58M |
Important Dates
The next estimated earnings date is Friday, May 24, 2024, before market open.
| Earnings Date | May 24, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
KYTX has 43.12 million shares outstanding.
| Shares Outstanding | 43.12M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.06
| Current Ratio | 3.06 |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -321.81 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -85.00% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$628,813 |
| Employee Count | 96 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (1Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 22.28 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 33.72 |
| Average Volume (30 Days) | 399,935 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -62.41M |
| Pretax Income | -60.37M |
| Net Income | -60.37M |
| EBITDA | -56.75M |
| EBIT | -60.18M |
| Earnings Per Share (EPS) | -$89.61 |
Balance Sheet
The company has $58.11 million in cash and $9.08 million in debt, giving a net cash position of $49.03 million or $1.14 per share.
| Cash & Cash Equivalents | 58.11M |
| Total Debt | 9.08M |
| Net Cash | 49.03M |
| Net Cash Per Share | $1.14 |
| Equity / Book Value | -131.40M |
| Book Value Per Share | -3.05 |
| Working Capital | 40.81M |
Cash Flow
In the last 12 months, operating cash flow was -$52.41 million and capital expenditures -$621,000, giving a free cash flow of -$53.03 million.
| Operating Cash Flow | -52.41M |
| Capital Expenditures | -621,000 |
| Free Cash Flow | -53.03M |
| FCF Per Share | -$78.73 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
KYTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -10.00% |
| FCF Yield | -8.79% |
Analyst Forecast
The average price target for KYTX is $39.50, which is 182.14% higher than the current price. The consensus rating is "Buy".
| Price Target | $39.50 |
| Price Target Difference | 182.14% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -43.98% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |